Nearly $7 Million in New Grants Drive Hairy Cell Leukemia Research Forward

In a significant boost for one of the rarest forms of blood cancer, the Hairy Cell Leukemia Foundation and Blood Cancer United, formerly known as The Leukemia & Lymphoma Society, have announced six new research grants worth nearly $7 million over the next five years. The awards, revealed on September 24, 2026, form part of the HCL2030 program, which continues and expands a six-year strategic partnership between the two organizations. The funding will support research at world-class institutions across the United States and Europe, targeting everything from the earliest steps of diagnosis to the development of all-oral treatment combinations for patients whose disease has returned.

Hairy cell leukemia is a rare hematological malignancy that affects the blood, bone marrow, spleen, and other organs. First described in the late 1950s, the disease is characterized by the overgrowth of abnormal white blood cells, which crowds out the production of normal blood cells and leaves patients vulnerable to infection, anemia, and bleeding complications. The cancer takes its name from a striking microscopic feature: the malignant cells carry short, thin, hair-like projections on their surface, giving them an unmistakable appearance under the microscope. Approximately 1,200 Americans receive a diagnosis each year, and for reasons that remain unknown, men are affected four times more often than women.

One of the most important conceptual advances in recent years has been the recognition that hairy cell leukemia is not a single disease but two distinct entities: classic hairy cell leukemia and hairy cell leukemia variant. Classic disease is by far the more common form, accounting for up to 90 percent of cases. Thanks to current treatments, most patients with classic hairy cell leukemia remain in remission for five to 15 years or more, a remarkable achievement for a blood cancer that once carried a grim prognosis. Variant disease, by contrast, is far more aggressive. Roughly 10 to 15 percent of patients have the variant form, which tends to respond less well to therapy, relapses more quickly, and carries a poor survival rate. Patients with classic disease who relapse also face a much worse outlook. Closing this gap between the success achieved in classic disease and the unmet needs of variant and relapsed patients is the central focus of the latest round of grants.

The six new awards zero in on a range of aspects of the disease, supporting patients from initial diagnosis and throughout their treatment. At The Ohio State University, Christopher Oakes, Ph.D., is working to advance understanding and classification of hairy cell leukemia in individual patients. Precise classification is the essential first step in ensuring that each patient receives the right treatment, particularly in a rare cancer where expertise is concentrated at a limited number of centers. At Dana-Farber Cancer Institute in Boston, Gregory Abel, M.D., M.P.H., is examining quality of life, decision-making, and outcomes for patients, acknowledging that survival is only one measure of success in a chronic disease that can require repeated courses of therapy.

At Stanford University in California, Gerlinde Wernig, M.D., is focused on finding new methods to improve disease prognosis, including understanding the factors that lead to relapse and to the development of variant disease. Her work addresses one of the deepest questions in the field: why some patients respond beautifully to treatment while others progress to more aggressive forms. At Case Western Reserve University in Cleveland, Reshmi Parameswaran, Ph.D., is examining how hairy cell leukemia becomes resistant to treatment and developing new therapeutic strategies for the variant form. Drug resistance is a central mechanism behind relapse, and unraveling it at the molecular level could open the door to treatments that overcome or prevent it.

Two of the grants support clinical trials testing combination therapies in Europe. Enrico Tiacci, M.D., at the University of Perugia in Italy, will be testing an all-oral combination treatment for patients whose hairy cell leukemia has relapsed. Tiacci’s involvement in this partnership is not new: his groundbreaking earlier work, also supported by research funds from this collaboration, established the drug vemurafenib as an alternative to the chemotherapy-based standard of care. Vemurafenib targets the BRAF mutation that drives the vast majority of classic hairy cell leukemia cases, and its success transformed the treatment landscape for relapsed patients who had exhausted conventional options.

Across the Atlantic, Francesco Forconi, M.D., Ph.D., at the University of Southampton in the United Kingdom, is testing whether a combination of two drugs that inhibit different proteins involved in hairy cell leukemia can produce deep, long-lasting remissions. The ambition behind his trial is a fixed-duration treatment paradigm: patients would stop therapy after a defined period and remain in remission, rather than having to take treatment indefinitely. For a rare cancer where patients may live for decades with their disease, the difference between lifelong therapy and a finite course with durable remission is profound, both medically and in terms of quality of life.

The scale and coordination of the HCL2030 program reflect a deliberate strategy for a rare disease. Because hairy cell leukemia affects relatively few patients, no single institution sees enough cases to drive major advances alone. Lore Gruenbaum, Ph.D., chief scientific officer at Blood Cancer United, emphasized this point, noting that medical research is not a solo sport. Even though researchers are working at different locations across two continents, she said, they are all very much on the same team, and that cooperation is particularly important for rare diseases such as hairy cell leukemia. It takes cooperation, time, and money, she added, to find the advances that will make a real difference for patients.

Anna Lambertson, executive director of the Hairy Cell Leukemia Foundation, framed the grants as the direct result of patient and family commitment to the cause. For patients with classic hairy cell leukemia, she noted, the field has achieved years and often decades of remission. Patients with variant disease, and those who relapse, deserve treatments that work just as well, she said, describing the grants as the way to close that gap. The Hairy Cell Leukemia Foundation, founded in 1984, is the only United States nonprofit solely focused on the disease. Founded and governed by patients, it funds innovative research, advances education, and provides peer support worldwide, and its patient-led mission has helped drive major treatment advances over four decades.

Blood Cancer United, the largest global nonprofit focused on blood cancer patient support, research, and advocacy, has served people affected by more than 100 types of blood cancer since its founding in 1949. The organization funds innovative research, offers free resources and personalized support, and advocates for more accessible and affordable healthcare for all patients. Together, the two organizations have turned the HCL2030 program into a coordinated engine for progress in a cancer that receives little attention relative to its impact on those it affects. With nearly $7 million in new investment now flowing to laboratories and clinics in the United States and Europe, the next five years promise advances in classification, prognosis, drug resistance, and treatment duration that could reshape the outlook for every hairy cell leukemia patient, particularly those with variant disease or relapse who have waited longest for options equal to those enjoyed by the majority.

Subject of Research: New research funding for hairy cell leukemia diagnosis, prognosis, and therapy development

Article Title: Nearly $7 million in new funding accelerates hairy cell leukemia research

Article References: Nearly $7 million in new funding accelerates hairy cell leukemia research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hairy cell leukemia, Blood Cancer United, Hairy Cell Leukemia Foundation, HCL2030, blood cancer research grants, variant hairy cell leukemia, vemurafenib, drug resistance, relapse, rare disease funding, combination therapy, all-oral treatment